Key result
Transcatheter PDA closure is linked to symptomatic improvement and reduced MR severity in ~86% of patients.
Why the study?
Hemodynamically significant patent ductus arteriosus can be associated with mitral regurgitation, but the fate of mitral regurgitation after initial transcatheter ductus closure required description.
Does transcatheter PDA closure reduce mitral regurgitation severity in patients with PDA and significant MR?
Observational (n=14)
No
Does transcatheter PDA closure reduce mitral regurgitation severity in patients with PDA and significant MR?
Answers are grounded in this paper and cite their sources.
Transcatheter closure of patent ductus arteriosus in patients with significant mitral regurgitation leads to symptomatic improvement and reduction in MR severity in the vast majority of cases.
A hemodynamically significant patent ductus arteriosus (PDA) may be associated with mitral regurgitation (MR). Available treatment strategies are - surgical PDA ligation ± mitral valve surgery and initial transcatheter PDA closure (PDA-DC) with treatment of MR subsequently, if necessary. We aimed to describe the fate of MR after PDA-DC in patients with PDA and significant MR. On retrospective review of electronic health records between 2013 and 2023, 14 eligible patients were identified. Amongst them, PDA-DC resulted in symptomatic improvement in all. A reduction in the severity of MR was noted in 12 patients (85.7 %).
No takes yet. Share an insight, caveat, or question.
Kartha et al. (2025) conducted an observational in Patent ductus arteriosus with significant mitral regurgitation (n=14). Transcatheter PDA closure (PDA-DC) was evaluated on Reduction in the severity of mitral regurgitation. Transcatheter closure of patent ductus arteriosus resulted in symptomatic improvement in all patients and reduced the severity of mitral regurgitation in 85.7% of cases.
Synapse has enriched 10 related papers. Consider them for comparative context: